Efficacy of camrelizumab assisted hepatic arterial chemoembolization in treatment of primary liver cancer and its effect on T lymphocyte subsets and tumor markers
Objective To analyze the clinical efficacy of using camrelizumab in combination with hepatic artery chemoembo-lization(TACE)in the treatment of primary liver cancer(PHC)patients,as well as the impact of this regimen on T lympho-cyte subsets and tumor markers.Methods Totally 82 original PHC patients admitted to Shangqiu Municipal Hospital from January 2021 to October 2023 were randomly divided into two groups using a random number table method.The control group(41 cases)received TACE treatment,while the study group(41 cases)received combined treatment with camrelizumab on the basis of the control group.Clinical efficacy data,tumor marker data,T lymphocyte subsets data,and adverse reactions were collected from all patients.Results The disease control rate of the study group was 92.68％higher than that of the con-trol group,which was 75.61％(P＜0.05);the levels of CD3+,CD4+,and CD4+/CD8+ in all post-treatment data in-creased compared to before treatment,and the study group[65.41±6.44)％,(42.71±5.63)％,(1.81±0.31)]showed more significant improvement(P＜0.05);after treatment,the levels of CD8+,alpha fetoprotein(AFP),carcinoem-bryonic antigen(CEA),and alpha fetoprotein heterogeney-3(AFP-L3)decreased in both groups compared to before treat-ment,and the study group[22.77±1.16)％,(92.98±10.28)ng/mL,(10.28±1.87)ng/mL,(182.24±15.63)ng/mL]showed a more significant decrease(P＜0.05);there was no statistically significant difference in the incidence of adverse reactions among all patients after treatment(34.15％ vs 17.07％)(P＞0.05).Conclusion The use of camrelizumab as an adjuvant therapy for TACE in PHC patients is beneficial for improving efficacy,reducing tumor marker expression,im-proving patient immune function,and not significantly increasing adverse reactions.
CamrelizumabPrimary liver cancerHepatic arterial chemoembolizationTumor markersImmune function
NETL
NSTL
万方数据
